The Other Agency: CMS Shocks Wall Street-and Amgen Takes a Hit
This article was originally published in RPM Report
Executive Summary
Biotech investors are used to worrying about what FDA will or won't do to a blockbuster drug, especially in the current climate of drug safety hysteria. But Wall Street didn't expect the federal Medicare agency to get into the act.
You may also be interested in...
EPO Market Stabilizes, But For How Long?
Amgen hoped it would be turning the page on the regulatory and reimbursement problems that dogged Aranesp and made 2007 a year to forget. But more negative data means another trip to an FDA advisory committee, and this time Wall Street is bracing for the worst.
FDA-CMS Parallel Reviews: Too Close for Comfort?
Parallel reviews by FDA and CMS are back on the table. While the proposed voluntary program seems harmless enough, drug and biotech companies may have good reason to be wary of greater collaboration between FDA and CMS officials.
FDA-CMS Parallel Reviews: Too Close for Comfort?
Parallel reviews by FDA and CMS are back on the table. While the proposed voluntary program seems harmless enough, drug and biotech companies may have good reason to be wary of greater collaboration between FDA and CMS officials.